HDAC3 inhibitors have been proposed as therapeutic targets to combat inflammation in COPD and asthma, since HDAC3 is a positive regulator of NF-κB mediated inflammation [33]. The gene discussed is HDAC3; the disease is chronic obstructive pulmonary disease.